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Abstract
Among the living organisms, Escherichia coli has been the most common choice 
employed for recombinant protein expression. In addition to its well-characterized 
genetics, E. coli is fast growing, relatively cheap, and easy to handle. These fine 
properties, in conjunction with the success achieved in transforming plasmid DNA 
into E. coli, as well as the advent of various genetic engineering techniques in the 
1970s, have enabled E. coli to be considered as the most favorable host for genetic 
manipulations. The recent advances in better comprehension of regulatory controls 
of gene expression and the availability of various novel approaches, which include 
both intracellular, e.g., through intein-mediated expression and self-cleavages, and 
extracellular, e.g., through the use of secretion signals, to achieve successful expres-
sion of the target proteins in E. coli further support the view that E. coli is the most 
promising host choice for heterologous protein expression.
Keywords: Escherichia coli, E. coli, recombinant protein expression, heterologous 
protein, authentic structures, fusion protein, affinity tags, secretion, excretion, 
inteins
1. Introduction
The achievements in unveiling the structure of DNA, deciphering the genetic code, 
understanding gene expression and regulation, and discovering extrachromosomal 
DNA (plasmid), restriction endonucleases and DNA ligases in the 1950s and 1960s laid 
the groundwork for the construction of the first chimeric (recombinant) DNA mole-
cule [1]. In 1973, Cohen and Boyer reported their success in creating the first Escherichia 
coli transformant into which a recombinant plasmid molecule was introduced [2].
The possibility of inserting foreign DNA into E. coli has not only allowed the 
development of a vast number of molecular biology techniques for genetic manipu-
lations, e.g., construction and characterization of cDNA libraries, DNA splicing and 
amplification, hybridization and sequencing, site-specific mutagenesis, research and 
applications of bacteriophages and DNA modifying enzymes, studies of regulation 
of gene expression, etc., but also the exploitation of E. coli for use as a surrogate 
host for the expression of heterologous proteins. Despite the presence of restriction 
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systems in E. coli [3, 4], foreign DNA from a wide variety of sources, ranging from a 
simple virus to a complex organism such as the human being, have been shown to be 
stably maintained in it. Therefore, although E. coli may not be employed as the final 
host cell for target protein expression, due to the difficulties of DNA manipulations, 
which include selection, characterization, and amplification of recombinant DNA 
constructs directly performed in the final host cell, E. coli is routinely recruited to 
fulfill the tasks. In this regard, E. coli acts as an indispensable stepping stone facilitat-
ing molecular genetic studies undertaken in eukaryotic and other bacterial host cells.
The fine properties including fast growth rate (with a doubling time of less than 
30 min), ease of manipulation, relatively low cost of cultivation/protein expression, 
and the well-characterized genetics of E. coli are the key reasons why this bacterium 
has been commonly involved in the wide range of studies mentioned above. Thus, 
E. coli has been crowned the most popular host of choice employed for heterologous 
protein expression.
Being a Gram-negative bacterium, E. coli possesses two layers of cell envelope, 
the inner/cytoplasmic membrane and the outer membrane, between which is the 
narrow periplasmic space (Figure 1). Except for specific strains, e.g., a colicin-
producing strain, E. coli does not produce proteins beyond the outer membrane 
in the living environment. Therefore, in the early days, E. coli was essentially 
employed for cytoplasmic/intracellular expression of recombinant proteins. 
However, the advancement of recombinant DNA technology in the 1970s–1980s not 
only enabled E. coli to serve as an efficient host system for protein expression but 
also facilitated E. coli to be transformed into a highly versatile expression platform, 
with which heterologous proteins may also be allowed to be produced in the culture 
supernatant. In addition, despite being expressed in the cytoplasm, target proteins 
resulting from a recently developed novel process, the intein-mediated expression 
approach [5, 6], have been shown to possess primary structures precisely the same 
as expected [7]. This new recombinant DNA approach may prove to be a practical 
Figure 1. 
Schematic representation of the subcellular compartments of E. coli available for expression of heterologous 
proteins. These compartments such as cytoplasm, periplasm, and culture medium are shown. For a secretory 
protein, it is initially formed as a preprotein ( ), which consists of a signal peptide ( ). The preprotein is 
directed to the SecYEG pathway. Before reaching the secretion channel ( ), the preprotein is unfolded by the 
SecB protein ( ), followed by interacting with the SecA protein ( ), which helps hydrolyze ATP to support 
the active transport of the preprotein. The signal peptide is then cleaved off from the preprotein subsequent to 
the passage of the latter through the SecYEG pathway.
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process for the recombinant production of medically valuable proteins that are 
preferred to share the authentic structures with their native counterparts.
Proteins expressed in eukaryotic cells are subjected to post-translational 
modifications (PTM), of which many of them do not appear to occur in E. coli 
cells. Despite this deficiency, E. coli is still the most common choice employed for 
the expression of eukaryotic proteins. For example, about 30% of the medically 
valuable proteins produced using recombinant DNA approaches are expressed 
employing E. coli as the host [8]. The finding of successful expression of eukaryotic 
proteins in E. coli suggests that many target proteins may not be posttranslationally 
modified, and even some of them are, PTM may not have a direct effect on func-
tional activities. The observation also supports the view that  E. coli will continu-
ously play an indispensable role in heterologous protein expression. In choosing 
the most appropriate tactic for the expression of a heterologous protein in E. coli, it 
is important that we understand both the target protein and the available methods 
of choice well. E. coli is recognized as being a “versatile” host from the perspective 
that it may facilitate heterologous protein expression in all three of the subcellular 
compartments including: (i) cytoplasm, (ii) periplasm, and (iii) culture medium 
(Figure 1). In this communication, we discuss how those compartments may 
be employed to express foreign proteins that share widely different biochemical 
properties, under the condition that the presence of PTM is not a prerequisite.
2. Expression of recombinant proteins in the cytoplasm of E. coli
The breakthrough achievements in the construction of recombinant DNA 
molecules [1] and the transformation of chimeric DNA constructs into E. coli [2] in 
the early 1970s have paved the way for rapid advances in the development of recom-
binant DNA approaches to the expression of a wide collection of useful/valuable 
proteins of various origins. Due to the aforementioned fine properties of E. coli, this 
Gram-negative bacterium has been extensively studied and exploited for use as a 
host to facilitate expression of heterologous proteins (Table 1).
2.1 Fusion protein approach
A common strategy in the expression of heterologous proteins is to fuse the 
target protein with a fusion partner, of which a familiar example is the enzyme 
β-galactosidase (β-Gal) expressed intracellularly in E. coli. Being well-characterized 
in terms of its structure and regulation of expression [27, 28], in the early days, 
β-Gal was one of the few E. coli products to be employed as a reporter protein, for 
which convenient detection assays [29] were available. Fusing the short mammalian 
somatostatin (Som) comprising only 14 amino acids (aa) to β-Gal, in 1977, Itakura 
et al. demonstrated (Figure 2), for the first time, successful expression of bioac-
tive recombinant somatostatin in E. coli [9]. In the work, Som was fused to β-Gal 
through the application of oligonucleotide assembly. Thus, expression of the two 
proteins, which was under the regulatory controls of the Lac operon, would result 
initially in a β-Gal-Som precursor. The β-Gal component played two important roles 
in the fusion: first, it offered a facile screening assay for the selection of potentially 
positive clones expressing β-Gal-Som; second, it served as a guardian protecting 
Som from being attacked by proteolytic degradation from the N-terminus.
Since Som is a short polypeptide consisting of only 14 aa residues [30], which 
does not consist of Met as a member, in engineering the aforementioned β-Gal-Som 
fusion, a Met residue was intentionally inserted precisely between β-Gal and Som, 
thus resulting in a β-Gal-Met-Som precursor in the work [9]. In vitro cleavage with 
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the chemical, CNBr, which specifically attacks Met, resulted in the separation of 
the fusion to yield authentic Som comprising 14 aa as the final product, which was 
subsequently shown to be bioactive (Figure 2) [9].
A similar approach was also applied to express bioactive human insulin in E. coli 
in 1979 (Figure 2), once again, taking advantage of β-Gal as the fusion partner and 
the absence of a Met residue in the polypeptide [10].
However, the above two examples appear to be the exception rather than the 
rule. Despite the application of β-Gal to serving as a fusion partner in many other 
cases of recombinant protein expression, due to the presence of one or more Met 
residues in the target proteins, the intriguing tactic of employing CNBr to cleave the 
fusion precursors to free the desired final protein to be impractical for routine use.
2.2 Direct expression
If a heterologous protein is insusceptible to proteolytic degradation by E. coli 
proteases, perhaps a simple method to achieve expression of the protein in E. coli is 
to clone its gene determinant downstream from a regulatory region comprising both 
the promoter and RBS sequences carried on a suitable expression vector. Examples 
Approach Examples Section 
concerned
References
Fusion expression Hormone somatostatin 2.1 [9, 10]
Human insulin
Direct expression Human growth hormone 2.2 [11–15]
Human fibroblast interferon
Human leukocyte interferon (LeIF A)
Human leukocyte interferon (LeIF B)
Mouse granulocyte-macrophage colony 
stimulating factor (mGM-CSF)
Tagged protein expression Human insulin-like growth factor I 
(IGF-1)
2.3 [16–18]
Human parathyroid hormone (hPTH)
Human fibroblast growth factor 21 
(hFGF21)
Intein-mediated Cre recombinase 3 [5, 6, 19, 
20]
Cecropin
Human basic fibroblast growth factor 
(bFGF)
Secretion/excretion Human epidermal growth factor 
(Secretion)
4 [21–26]
Hirudin
Human growth hormone (hGH)
Human granulocyte-macrophage colony 
stimulating factor (Hgm-CSF)
Human epidermal growth factor 
(Excretion)
Table 1. 
Various approaches for heterologous proteins expression in E. coli.
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including human growth hormone [11], human hemoglobin [31], interleukin [32], 
etc., have been expressed in E. coli using this approach (Figure 2).
The alignment between the target gene and its expression regulatory elements 
could be conveniently achieved using site-directed mutagenesis. However, the 
translation initiator, N-formyl-methionine (fMet), which is present in proteins 
formed in bacteria, may cause adverse effects on the bioactivity and stability of the 
target protein [33]. The efficiency of removal of fMet in the cell is incomplete and is 
highly dependent on the adjacent two residues next to the initiator [34, 35].
Various strategies have been described to remove fMet from heterologous 
proteins including the use of both in vivo and in vitro approaches [34, 36, 37]. 
However, none of the available protocols is able to result in a homogeneous product 
that is free of fMet [34, 36]. The target protein, being contaminated by the presence 
of the undesirable fMet-bearing variant, may exhibit increased immunogenicity 
[33] and reduced levels of stability and bioactivity [34], which might have a correla-
tion with fMet which has been speculated to serve as a degradation signal [38].
2.3 Applications of affinity tags
A major goal in recombinant DNA expression is to achieve efficient pro-
duction of a target protein on a large scale. Common strategies including the 
use of: (1) plasmids with increased copy numbers such as the ones employing 
runaway replicons [39, 40]; (2) strong transcriptional control signals including 
PL, Tac, and T7 promoters [41, 42]; (3) efficient ribosome binding sites such 
as the Shine-Dalgarno sequence [43]; (4) inducible promoters which may be 
activated by heat shocking [44], light induction [45] or chemicals, e.g., isopropyl 
Figure 2. 
Schematic diagram depicting the major components included in various expression constructs for recombinant 
protein expression in E. coli. Regulation region ( ) includes the promoter ( ), operator, and ribosome 
binding site. Other components including the ATG start codon ( ), and coding sequences for fusion tag ( ), 
e.g., β-Gal in Approach 1(a), GST, 6xHis-tag, or MBP in Approach 1(b); signal peptide ( ) in Approach 4; 
chitin-binding domain ( ); target proteins ( ); intein ( ) are also shown. Cleavage sites on fusion 
proteins (Approach 1a and 1b) and intein-target protein precursors are indicated ( ).
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β-D-1-thiogalactopyranoside (IPTG); (5) a codon-optimized gene sequence [46, 
47]; and (6) an efficient plasmid maintenance system. These various methods 
have been commonly applied, either individually or in conjunction with a fusion 
approach, to achieving efficient expression of target proteins in E. coli.
Although high yields of products may result from the application of above 
mentioned expression approaches, oftentimes, the products present themselves as 
insoluble inclusion bodies or aggregates. Unfortunately, these inclusion bodies are 
composed of denatured and misfolded proteins, which are functionally inactive 
[48, 49]. Due to the rearrangements of disulfide bridges in the aggregates, despite 
going through the processes of denaturation and renaturation, the target proteins 
are unlikely able to regain their functional activities [48].
Fusion of a target protein to an affinity tag presents a viable approach to not 
only the purification of the final product, but also the preservation of the product 
as a soluble protein. It has been shown that protein tags such as maltose-binding 
protein [50], glutathione S-transferase [51], small ubiquitin modifying protein 
[52, 53], and thioredoxin [54] might help improve the solubility of fusion prod-
ucts formed between the tags and target proteins (Figure 2). Given that a fusion 
product is expressed as a soluble and properly folded intermediate, and that it is 
readily purified using affinity chromatography and proteolytically processed at a 
recognition site engineered between the tag and target proteins, the frailty of this 
fusion approach is how the affinity tag may be removed from the target protein on 
condition that the latter till possesses the peptide sequence as stipulated. Thus, this 
approach may not be able to meet the stringent demand from therapeutic proteins 
of which any discrepancy found in their primary structures may result in undesir-
able side effects such as increased immunogenicity [33], reduced levels of stability 
and bioactivity [34, 55, 56], and worse still, greater tendency to promote malig-
nancy. It is believed that target proteins bearing the authentic structures are as safe 
as their native counterparts in performing biological functions [57].
3. Intein-mediated expression of heterologous proteins
3.1 Inteins as fusion partners
Since the first intein, or protein intron, was discovered in the late 1980s [58], 
over 600 putative intein genes have been discovered [59]. Being able to undergo 
autocatalytic cleavages of themselves from sequences flanking their two termini, 
the N- and C-exteins, the application of inteins to the development of E. coli expres-
sion platforms has revolutionized the production of recombinant proteins in two 
different facets. First, fusion proteins formed between inteins and target proteins 
may undergo auto-cleavage activities in the cytoplasm of E. coli [5, 6, 60–63]. 
Second, despite taking place intracellularly, the detached target proteins possess the 
requisite structures, e.g., the authentic N-terminal sequences which are the same as 
those of their native counterparts [5, 6, 60–63].
3.2 Autocatalytic cleavages of intein-target fusion proteins: through an in vitro 
method
In the early days of exploiting the application of inteins to protein expression, fusion 
precursors formed among three components, comprising an N-terminal protein tag, 
a common example being a chitin-binding domain (CBD; [64]), a central intein, and 
a C-terminal target protein (CBD-I-TP), were frequently expressed as biologically 
inactive inclusion bodies in the cytoplasm of E. coli [65–67]. Subsequent to denaturation 
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and renaturation of the protein aggregates [67], the renatured precursors comprising 
CBD and the target proteins, e.g., Cre recombinase, α-1-antitrypsin, human epidermal 
growth factor [67] (Figure 2), collected in a chitin column was cleaved [64] by modu-
lating the environmental conditions to release the target proteins [67] (Figure 3).
Being expressed as inclusion bodies, as discussed in Section 2.3, it is unlikely 
that the renatured CBD-I-TP molecules would all be bound to the chitin matrix or 
be correctly refolded. Therefore, the above described intein-mediated expression 
process working in conjunction with an in vitro autocatalytic cleavage protocol is 
expected to result in a substantial loss of bioactive target proteins.
3.3 Autocatalytic cleavages of intein-target fusion proteins: in vivo
Despite the inducibility of self-cleavages of inteins by modulating the environ-
mental conditions [68], the exact mechanisms regarding how the induction works is 
not clear. Recent findings have shown that the ability of an intein element in fusion 
proteins to undergo self-cleavages appears to be dependent upon the presence of a pair 
of “well-matched” heterologous “exteins.” If this condition is fulfilled, autocatalytic 
cleavages might take place at the two terminal junctions where the intein is fused with 
the two exteins (Figure 3). It was demonstrated that when human epidermal growth 
factor (EGF) and basic fibroblast growth factor (bFGF) were precisely fused at the N- 
and C-termini, respectively, of the Sce VMA intein, auto-cleavage processing occurred 
[5] (Figure 2). Both EGF and bFGF were retrieved and shown to share not only 
authentic structures, but also potent bioactivities with their native counterparts [5].
Figure 3. 
Processing of precursors formed between inteins and target proteins. The processing may be achieved by one of 
the following two methods: (A) induced in vitro cleavage; (B) in vivo cleavage. To attain a soluble precursor 
protein for processing in (A), the insoluble precursor protein express in the host cells is first required to be 
denatured and renatured. The solubilized precursor is then adsorbed onto an affinity column containing, e.g., 
chitin resin; changes of the conditions in the column may result in self-cleavage and hence the detachment of the 
target protein. In (B), the self-cleavage reaction takes place automatically in the host without extra input of 
effort. In the figure, hatched box ( ) denotes affinity tag, white box ( ) denotes intein, dotted box 
( ) denotes target protein and affinity resin is denoted by . The correctly folded affinity tag, intein, and 
target protein are denoted as , and,  respectively. However, the in vitro cleavage process shown in 
(A) may also result in incorrectly folded proteins.
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Moreover, since EGF was fused to the OmpA signal peptide (OmpA) in the 
abovementioned work (Figure 2), the EGF-VMA-bFGF fusion was also shown to be 
secretory and both EGF and bFGF were finally detected to be present in the culture 
medium of their E. coli host [5]. Interestingly, when EGF was absent in the fusion, 
thus leaving the formation of OmpA-VMA-bFGF, and when the positions of EGF 
and bFGF in the fusion were switched, thus leading to the expression of OmpA-
bFGF-VMA-EGF, neither of the two precursors resulted in successful self-cleavages 
to yield authentic bFGF as the final product [5]. The results support the idea that 
not only the presence of a matched pair of exteins, but also their relative position in 
the fusion is important in effecting autocatalytic cleavages of the extein from their 
intein fusion partner.
Another noteworthy observation from the above work is the soluble nature of 
the fusion precursor, EGF-VMA-bFGF. This unusual condition, which contrasts 
markedly with the results of insoluble aggregates reported previously [64], has 
facilitated auto-cleavages of the fusion precursor to undergo self-cleavages directly 
in the cytoplasm, thereby avoiding the involvement of a time-consuming and inef-
fective process of denaturation and renaturation, followed by the extra time and 
effort spent on implementing the in vitro cleavage operation (Figure 3).
The in vivo autocatalytic processing approach introduced above may also be 
extended for use in the co-expression of other target proteins [60] (Figure 4). 
Moreover, through a combined protocol of gene amplification and refined fed-batch 
fermentation, the EGF-VMA-bFGF fusion has been upgraded to result in an expres-
sion of EGF-VMA-bFGF-VMA-bFGF as the precursor in E. coli [6]. Despite 92% 
bigger in size than EGF-VMA-bFGF, which was shown to have a mass of 73 kDa [5], 
EGF-VMA-bFGF-VMA-bFGF was found to be expressed as a soluble protein, which 
was still able to undergo autocatalytic cleavages to result in authentic and bioactive 
Figure 4. 
Analysis of the CBD-DnaB-IFN precursor by polyacrylamide gel electrophoresis. Cell lysate samples were 
prepared from E. coli transformants harboring plasmid pTWIN-CBD-DnaB-IFN grown in 2 × YT medium 
before and after 4 h of IPTG induction. Cell pellets were lysed by a chemical lysis protocol as described 
previously [5]. Lanes containing soluble proteins retrieved from the clear lysate (CL) and insoluble proteins 
retrieved from cell debris (Deb) were resolved as shown. The products CBD-DnaB ( ) and IFN ( ) resulting 
from autocatalytic cleavages of CBD-DnaB-IFN are denoted.
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bFGF as the final product [6, 61–63]. In addition, fermentative production of EGF-
VMA-bFGF-VMA-bFGF resulted in a dramatic improvement in the yield bFGF, 
amounting to 610 mg L−1 of cell culture [6], which was over 2.4 times higher than 
that resulting from the processing of EGF-VMA-bFGF expressed previously [5].
4.  Expression of heterologous proteins across the inner membrane of  
E. coli
The approach of secretory expression of heterologous proteins stemmed from 
the work of W. Gilbert’s group, which employed the N-terminal 23 amino acid 
leader sequence of the E. coli penicillinase [69], to direct secretion of eukaryotic 
proteins, using rat proinsulin as the model protein, to the periplasmic space of  
E. coli in the late 1970s and early 1980s [69–72]. The secreted proinsulin was not 
only shown to possess an authentic structure, with the cleavage of the signal peptide 
done precisely [71], but also shown to be more stable than its cytoplasmic counter-
parts fused to defective signal sequences [72]. Over the next few years, different 
eukaryotic proteins, e.g., EGF [21], human interferon-α [73], hirudin [22], human 
growth hormone [23], and human granulocyte-macrophage colony stimulating fac-
tor [24], were also successfully expressed though secretion using various bacterial 
signal peptides in E. coli (Figure 2).
Meanwhile, E. coli mutants that were able to leak endogenous enzymes from the 
periplasm were isolated [74, 75]. The results suggested that heterologous proteins 
might also leak from the periplasm to the culture medium in E. coli. As expected, a few 
years later, heterologous proteins including bacterial endoglucanases [76, 77], a peni-
cillinase of an alkalphilic Bacillus [78], as well as human proteins, such as β-endorphin 
[79], EGF, parathyroid hormone, and interleukin-6 [80], were expressed as extracel-
lular products using either wildtype or leaky E. coli strains as hosts.
Not all proteins, e.g., the cytoplasmic enzyme—β-galactosidase, may be pos-
sibly expressed as secreted or excreted products in E. coli, despite their fusions to 
secretory proteins [81, 82] or directly to the signal peptides of these proteins [83]. 
Intracellular proteins do not appear to possess a molecular structure that is compat-
ible with the SecYEG pathway, the major translocation machinery located in the 
inner membrane for protein transport [70, 82, 84–86]. On the other hand, when a 
naturally secreted target protein, e.g., EGF, is fused to a signal peptide, it may end 
up as a mature protein in either the periplasm [21] or the culture medium [80] of  
E. coli cells, depending essentially upon the efficiencies of expression and secretion 
of the protein (see below).
4.1 Secretory expression of target proteins in E. coli
In E. coli, several protein export systems, including the SecYFG (a trimeric 
complex comprising three polypeptides: SecY, SecE and SecG), Tat (twin-arginine 
translocation), and SRP (signal recognition particle) pathways which are embedded 
in the inner or cytoplasmic membrane, are responsible for the transport of proteins 
from the cytoplasm to the periplasm [86–89] (Figure 1). Among them, the SecYEG 
translocon is a general, conserved, and essential pathway which is found in both 
prokaryotic and eukaryotic cells [85, 86]. Being the major protein transport system, 
over 90% of the translocated proteins are secreted through the SecYEG pathway 
[87, 88] (Figure 1).
To enable proteins to be secreted using the SecYEG translocon, they are required 
to be expressed first as preproteins, which are fused at their N-termini with a short 
(commonly less than 24 amino acids) signal peptide [87]. In the cytoplasm, a 
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preprotein is maintained in an extended (export-competent) state by interacting 
with the SecB chaperone. Subsequent to an interaction formed between the signal 
and the SecA ATPase, the preprotein-complex then associates with the SecYEG path-
way. With repeated pushes of SecA, the preprotein is secreted through the translocon 
in an ATP-dependent manner, followed by removal of the signal peptide by signal 
peptidase before the mature protein is released to the periplasm [87, 89, 90].
A wide range of heterologous proteins including degradative enzymes [91, 92], 
human hormones, and growth factors [5, 25, 26] have been successfully expressed 
as secretory proteins in E. coli. Many of the secreted proteins were not only shown 
to be bioactive, but also confirmed by sequence determination to possess the correct 
structures, supporting that the signal peptides fused at the N-termini of the pre-
proteins had been removed correctly during the process of secretion [5, 25]. These 
advantages, together with lower levels of protease complexity and activity [72], and 
the relatively more oxidative environment that may help proper folding and disul-
fide-linkage formation [93, 94], enable the periplasmic space to be consider as a 
reasonable and appropriate destination for the expression of recombinant secreted 
proteins. Later on, with the help of various genetic and/or biochemical manipula-
tions [95], or even merely through improving the levels of the secreted proteins 
concerned, which was referred as the “self-driven approach” [95], interestingly, the 
target proteins might then to be allowed to leak out to the culture medium, a process 
termed excretion, which is essentially caused by non-specific leakage of periplasmic 
proteins (see below).
4.2 Excretory production of target proteins in E. coli
In the mid-1980s, researchers from different groups discovered that heter-
ologous proteins expressed and secreted to the periplasm of E. coli might also be 
further excreted to the culture supernatant [22, 79]. For example, the development 
of sensitive screening assays, e.g., the Congo red plate assay (Figure 5), helped 
to confirm that the detection of a recombinant endoglucanase (Eng) encoded by 
the cenA gene of a Gram-positive bacterium, Cellulomonas fimi [77, 91, 96], in the 
culture supernatant of its E. coli host was due to a new phenomenon, excretion 
(extracellular production), rather than from cell lysis.
Efficient expression regulatory elements such as the strong promoters includ-
ing tac, pL, and T7 [97, 98], the consensus ribosome binding site [99], the coding 
sequence for the potent OmpA signal [100], an effective inducible system, e.g., 
the lac operator/repressor system for transcriptional regulation [101, 102], etc., 
which are carried on a stable and high-copy number vector, e.g., pUC18 [103], have 
been made available to improve not only secretory, but also excretory expression 
of a wide variety of proteins in E. coli. The achievement of this research milestone 
was well exemplified by the development of an efficient protocol for extracellular 
production of EGF [104]. In early attempts to express EGF as a secretory protein 
in E. coli, the relatively weak phoA promoter was employed to perform transcrip-
tion of the egf gene and the less efficient PhoA signal peptide to direct EGF for 
secretion. Despite the demonstration of EGF secretion, the EGF detected in the 
periplasm was only at a considerably low level of 2.4 mg L−1 [21]. However, when 
the tac promoter and the ompA leader sequence were employed to facilitate EGF 
expression and secretion, respectively, it was shown that the level of excreted, but 
not secreted, EGF was markedly improved in E. coli cells [80](Figure 6). Moreover, 
further improvements in EGF expression resulted in a dramatic increase in the yield 
of excreted EGF [26, 95, 104, 105]. Similar trends were observed in increasing the 
levels of excretory production of other heterologous proteins, e.g., C. fimi cellulases 
Eng [91, 106, 107] and exoglucanase, as well as bFGF [6].
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4.3 Difficulties in implementing an effective excretory process and potential 
solutions
The findings described above support the view that excretion is a promising 
approach for recombinant production of heterologous proteins in E. coli. However, 
it has been shown that not all naturally secreted proteins may be expressed using 
excretion, despite using efficient transcriptional and translational controls, as 
well as effective secretion signal. For example, using the same regulatory elements 
which enabled a high level (325 mg L−1) of excretion of the 53-amino acid (aa) 
EGF peptide in E. coli [26, 95, 104, 105], attempts to produce authentic bFGF (146 
residues) by excretion in E. coli were unsuccessful [5]. One might wonder whether 
the discrepancy between the results of EGF and bFGF excretion was due to the 
marked difference between their molecular sizes. However, cellulases such as Eng 
and Exg, which possess large mature forms comprising 418 aa [91] and 443 aa 
[108],  respectively, have been shown to be efficiently produced by excretion in  
E. coli [92, 107, 109]. Therefore, in addition to the molecular size of a heterologous 
protein which might have some effect on the efficiency of excretory production of 
the protein (see below), it appears that other factor(s), which may be associated 
to either the protein itself or the host (or both), play a crucial role in determining 
whether a protein may be expressed as a secretory/excretory product or not.
A major hurdle for excretory production of heterologous products is the 
dramatic cell death during enhanced expression of the preproteins—the fusion 
precursors formed between signal peptides and target proteins. A model designated 
“Saturated Translocation” was proposed to explain the phenomenon of cell lethality 
resulting from hyper-expression of the preproteins [110]. According to the model, 
when a preprotein exceeded a tolerable level, it would saturate the capacity of the 
SecYEG pathway and interfere with its normal function in exporting endogenous 
proteins. These functional disorders resulted finally in cell death [110]. The model 
also explained why heterologous proteins of different sizes, which were undergoing 
secretory expression, would trigger rapid cell death (Figure 7) if the presence of 
their preproteins had exceeded their individual allowable thresholds, the “Critical 
Values (CV).” A CV is defined as the largest quotient between an intracellular 
Figure 5. 
E. coli transformants expressing excreted Eng. Making use of a convenient and sensitive agar plate assay based 
on the ability of Eng to degrade carboxymethylcellulose (CMC), and the affinity of the dye Congo red for 
long molecules of CMC, E. coli cells excreting Eng were detected. In this assay, CMC molecules are degraded 
randomly by Eng to generate oligomers of the substrate. These oligomers, especially those with fewer than five 
sugar units, bind poorly to Congo red. Hence, after staining with Congo red and destaining with salt solution, 
clear zones where CMC has been hydrolyzed by Eng are revealed [110].
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preprotein and its secreted mature counterpart that was tolerable by the host cells 
[92]. Deletion of the signal peptide from its mature partner, despite the possibility 
of incurring the formation of inclusion bodies [48], interestingly it would help 
avoid the onset of the deadly effect resulting from an efficiently expressed secretory 
protein [110]. The results clearly indicate that the bottleneck of secretory/excretory 
production of a heterologous protein is at the stage of secretion.
Different approaches have been attempted to attain or even improve the 
CV, and hence the maximum production of a secretory heterologous protein 
on a per cell basis. Since cell death results from hyper-expression, strategies 
of optimizing, rather than maximizing, protein expression, e.g., less efficient 
promoters [92, 107, 111] and start codon [92], as well as defined minimal media 
and sub-optimal cultivation conditions [26] have been employed and shown to 
provide beneficial effects. More encouragingly, excretory production of Exg was 
Figure 6. 
Excretory production of EGF in E. coli. Protein concentrations and enzymatic activities detected in different 
subcellular compartments: cytoplasm, periplasm, and culture supernatant of E. coli transformants expressing 
EGF are shown. The samples prepared for various measurements were taken from the E. coli cell culture grown 
for 12 (A) and 24 h (B) after IPTG induction. The culture conditions employed were as described previously 
[80]. The results show that the EGF activities detected in the culture supernatant samples were the highest in 
all three compartments. However, beta-galactosidase activity was undetectable in the supernatant samples, 
supporting the conclusion that EGF activities detected in the supernatant samples resulted from excretion rather 
than from cell lysis.
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markedly enhanced when the level of Phage shock protein A (PspA) was elevated 
in the same host [109]. In the presence of additional PspA, the CV of secretory 
Exg was shown to be markedly increased from 20/80 to 45/55 [109]. Presumably, 
PspA helped the host cells to maintain membrane integrity and an energized 
membrane [112–114], which was readily equipped to cope with the “stress,” the 
presence of secretory Pre-Exg, by efficiently transporting it through the SecYEG 
pathway [109].
5. Conclusions
Since the advent of recombinant DNA technology in the 1970s, E. coli has 
been the most favorable host choice for the expression of heterologous proteins. 
Strategies including both intracellular and secretory methods have been designed 
for the expression of proteins of interest. Despite possessing an outer membrane, 
a wide variety of naturally secreted proteins including hormones, factors, and 
degradative enzymes have also been shown to be produced as extracellular 
(excreted) products in E. coli. In undertaking both intracellular and secretory/
excretory protein expression, a fusion approach is commonly adopted. Affinity tag 
proteins including β-galactosidase, glutathione S-transferase, and 6xHis-tag have 
been employed to form fusion precursors with desired proteins. To enable separa-
tion between the tag and target proteins, a protease cleavage site is required to be 
placed between the two proteins. However, on the one hand, it may be difficult to 
achieve the exact processing result through proteolytic cleavage. On the other hand, 
it is cost-ineffective to implement proteolytic cleavage on a large scale. Fusions of 
target proteins with inteins and secretion signal peptides have presented a practi-
cal approach to protein cleavages in cells without relying on the use of external 
proteases. It has been well demonstrated that using both methods of protein fusion, 
target proteins possessing the exactly processed sequences are obtainable through 
autocatalytic or signal peptidase cleavages in vivo in E. coli.
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Figure 7. 
Time-course experiments on extracellular expression of EGF and Exg in E. coli. (A) Measurements of EGF 
activities detected in the culture medium ( ) and viable cell counts ( ) of E. coli transformants 
harboring plasmid pWKW2 are shown (unpublished results). (B) Measurements of Exg activities detected in 
the culture medium ( ) and viable cell counts ( ) of E. coli transformants harboring plasmid 
tacIQpar8cex are shown. One unit of Exg activity in hydrolyzing p-nitrophenyl-β-D-cellobioside is defined as 
one nmol of p-nitrophenol produced per min. The growth conditions and IPTG induction of the cultures were 
done as described previously [111].
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β-gal β-galactosidase
CBD chitin-binding domain
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CNBr cyanogen bromide
CV critical value
DnaB DnaB helicase
EGF epidermal growth factor
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fMet N-formyl-methionine
GST glutathione S-transferase
I Intein
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MBP maltose-binding protein
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OmpA outer membrane protein A
PhoA alkaline phosphatase
Pre- premature
PspA phage shock protein A
PTM post-translational modification
Sce Saccharomyces cerevisiae
SDA self-driven approach
SecYEG trimeric complex of SecY, SecE, and SecG
Som somatostatin
Ssp Synechocystis species
TP target protein
VMA vacuolar ATPase subunit
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